Pharmaceuticals, Biotechnology and Life Sciences
Shield Therapeutics said Tuesday that Australia’s Therapeutics Goods Administration has registered its lead product Feraccru in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anaemia in adults.
Shield Therapeutics said Monday that US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA)…
Shield Therapeutics’s Feraccru can now be used as a treatment of all adults with iron deficiency (ID) as the company…
Shield Therapeutics said it was encouraged by the the demand of its its recently approved product for the treatment of iron…